Your session is about to expire
← Back to Search
Monoclonal Antibodies
Cosibelimab + Ublituximab + Bendamustine combination for Non-Hodgkin's Lymphoma
Phase 1
Waitlist Available
Research Sponsored by TG Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights
Summary
This trial is testing a new treatment for people whose B-cell Non-Hodgkin's Lymphoma has come back or didn't respond to previous treatments. The treatment uses a drug called cosibelimab alone or combined with two other drugs, ublituximab and bendamustin. These drugs help the immune system fight cancer and directly attack cancer cells.
Eligible Conditions
- Richter's Transformation
- Non-Hodgkin's Lymphoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Adverse Events That Are Related to Treatment
Secondary study objectives
Overall Response Rate
Trial Design
3Treatment groups
Experimental Treatment
Group I: Cohort CExperimental Treatment1 Intervention
Cosibelimab + Ublituximab + Bendamustine combination
Group II: Cohort BExperimental Treatment1 Intervention
Cosibelimab + Ublituximab + Bendamustine combination
Group III: Cohort AExperimental Treatment1 Intervention
Cosibelimab (TG-1501) single-agent
Find a Location
Who is running the clinical trial?
TG Therapeutics, Inc.Lead Sponsor
38 Previous Clinical Trials
6,808 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger